# Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

> **NCT00508274** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00508274
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07-18
- **Primary completion:** 2015-12-02
- **Final completion:** 2020-07-01
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508274, "Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00508274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*